UNICREDIT BANK/CALL/ROCHE GS/320/0.1/18.06.25 Stock

Warrant

DE000HD1QYM6

Real-time BOERSE MUENCHEN 05:46:06 2024-06-03 EDT
0.21 EUR +5.00% Intraday chart for UNICREDIT BANK/CALL/ROCHE GS/320/0.1/18.06.25
Date Price Change
24-06-03 0.21 +5.00%
24-05-31 0.2 +5.26%
24-05-30 0.19 0.00%
24-05-29 0.19 -5.00%
24-05-28 0.2 0.00%

Real-time BOERSE MUENCHEN

Last update June 03, 2024 at 05:46 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer UniCredit UniCredit
WKN HD1QYM
ISINDE000HD1QYM6
Date issued 2024-01-08
Strike 320 CHF
Maturity 2025-06-18 (381 Days)
Parity 10 : 1
Emission price 0.51
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.52
Lowest since issue 0.16
Delta0.09x
Omega 9.794
Premium38.66x
Gearing110.32x
Moneyness 0.7259
Difference Strike 87.75 CHF
Difference Strike %+27.42%
Spread 0.01
Spread %4.55%
Theoretical value 0.2150
Implied Volatility 23.22 %
Total Loss Probability 94.31 %
Intrinsic value 0.000000
Present value 0.2150
Break even 322.10 €
Theta-0.01x
Vega0.04x
Rho0.02x

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus